Eficacy of Dapagliflozin in Patients with Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Trial Study
Heart failure (HF) with preserved ejection fraction (HFpEF) is a major clinical difficulty caused by the existence of restricted therapeutic alternatives. Sodium-glucose cotransporter-2 inhibitors, including dapagliflozin, have demonstrated possible benefits in the therapy of HF. A randomized controlled...